Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity
暂无分享,去创建一个
Sourav Bandyopadhyay | N. Yosef | D. Nomura | David DeTomaso | A. Goga | Daniel K. Nomura | Rebecca A. Kohnz | L. Roberts | Lara Bideyan | Peter Yan
[1] Paul A Clemons,et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. , 2015, Cancer discovery.
[2] D. Sabatini,et al. Cancer cell metabolism: one hallmark, many faces. , 2012, Cancer discovery.
[3] M. Sperandio. The expanding role of α2‐3 sialylation for leukocyte trafficking in vivo , 2012, Annals of the New York Academy of Sciences.
[4] G. Adema,et al. Sialic acids sweeten a tumor's life. , 2014, Cancer research.
[5] M. Sola-Penna,et al. Epithelial Mesenchymal Transition Induces Aberrant Glycosylation through Hexosamine Biosynthetic Pathway Activation* , 2016, The Journal of Biological Chemistry.
[6] P. Dhawan,et al. Role of CXCL1 in tumorigenesis of melanoma , 2002, Journal of leukocyte biology.
[7] E. Papadimitriou,et al. Cell surface nucleolin as a target for anti-cancer therapies. , 2014, Recent patents on anti-cancer drug discovery.
[8] F. Balkwill. Cancer and the chemokine network , 2004, Nature Reviews Cancer.
[9] Gerald C. Chu,et al. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.
[10] Melinda M. Mulvihill,et al. Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. , 2015, ACS chemical biology.
[11] P. Dawson,et al. Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA‐N‐5 neuroblastoma cells , 2000, Journal of neuroscience research.
[12] Heike Knüpfer,et al. Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.
[13] K. Fisher,et al. Mapping Proteome-Wide Targets of Environmental Chemicals Using Reactivity-Based Chemoproteomic Platforms. , 2015, Chemistry & biology.
[14] S. Hofmann. Palmitoyl-Protein Thioesterase , 2002 .
[15] Kyung-Soon Park,et al. ELK3 Expression Correlates With Cell Migration, Invasion, and Membrane Type 1-Matrix Metalloproteinase Expression in MDA-MB-231 Breast Cancer Cells. , 2015, Gene expression.
[16] C. Thompson,et al. The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.
[17] S. Jakowlew. Transforming growth factor-beta in cancer and metastasis. , 2006, Cancer metastasis reviews.
[18] H. Coller,et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. , 2010, Genes & development.
[19] D. Legler,et al. Distinct CCR7 glycosylation pattern shapes receptor signaling and endocytosis to modulate chemotactic responses , 2016, Journal of leukocyte biology.
[20] P. Yaswen,et al. A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells , 2009, PloS one.
[21] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[22] C. Bertozzi,et al. Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation , 2007, Nature Protocols.
[23] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[24] Jeong-Seok Nam,et al. Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation , 2012, Cancer science.
[25] G. Dawson,et al. Palmitoyl Protein Thioesterase 1 Protects Against Apoptosis Mediated by Ras—Akt—Caspase Pathway in Neuroblastoma Cells , 2000, Journal of neurochemistry.
[26] M. Bryś,et al. O-GlcNAcylation and Metabolic Reprograming in Cancer , 2014, Front. Endocrinol..
[27] Julia Jellusova,et al. Regulation of B Cell Functions by the Sialic Acid-Binding Receptors Siglec-G and CD22 , 2011, Front. Immun..
[28] R. Takimoto,et al. RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells , 2014, Gastric Cancer.
[29] S. Kurtzman,et al. Interleukin-1 Family Expression in Human Breast Cancer: Interleukin-1 Receptor Antagonist , 2000, Cancer investigation.
[30] Daniel K Nomura,et al. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. , 2012, Cell metabolism.
[31] A. Giordano,et al. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model , 2015, Oncotarget.
[32] S. Jakowlew. Transforming growth factor-β in cancer and metastasis , 2006, Cancer and Metastasis Reviews.
[33] Björn Usadel,et al. Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..
[34] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[35] K. Schwertfeger,et al. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. , 2010, Current drug targets.
[36] P. Crocker,et al. New Functions for the Sialic Acid‐Binding Adhesion Molecule CD22, a Member of the Growing Family of Siglecs , 2001, Scandinavian journal of immunology.
[37] M. Hou,et al. Inhibition of Chemokine (C-C Motif) Receptor 7 Sialylation Suppresses CCL19-Stimulated Proliferation, Invasion and Anti-Anoikis , 2014, PloS one.
[38] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .